Drug Trial Radar · NCT02584933
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Last checked: Nov 20, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
233
Actual
Start
Dec 11, 2015
Primary completion
Jun 9, 2027
Study completion Jun 9, 2027
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Oct 23, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The rollover study will provide ceritinib to patients who are currently receiving treatment with ceritinib within a Novartis-sponsored study and in the opinion of the investigator, would benefit from continued treatment with ceritinib.
Conditions
- ALK Positive Malignancies
Interventions
ceritinibDrug
hard gelatin capsule or hard tablet for oral use up to 750 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: Until no patients are left on study up to 5 years
Locations
71 sites in 21 countries. Site status is shown where the registry gives one.
Highlands Oncology Group
Fayetteville, Arkansas
Loma Linda University
Loma Linda, California
University of Colorado Cancer Center
Aurora, Colorado
Maryland Oncology Hematology P A
Rockville, Maryland
Essex Oncology of North Jersey PA
Belleville, New Jersey
Novartis Investigative Site
Auckland, Australia
Novartis Investigative Site
Melbourne, Victoria, Australia
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Natal, Rio Grande do Norte, Brazil
Novartis Investigative Site
Porto Alegre, Rio Grande do Sul, Brazil
Novartis Investigative Site
Barretos, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Sofia, Bulgaria
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Guangzhou, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Guangzhou, Guangdong, China
Novartis Investigative Site
Changchun, Jilin, China
Novartis Investigative Site
Montería, Colombia
Novartis Investigative Site
Brno, Czechia
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Saint-Herblain, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Regensburg, Bavaria, Germany
Novartis Investigative Site
Cologne, North Rhine-Westphalia, Germany
Novartis Investigative Site
Hong Kong, Hong Kong
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Novara, Italy
Novartis Investigative Site
Bergamo, BG, Italy
Novartis Investigative Site
Bologna, BO, Italy
Novartis Investigative Site
Brescia, BS, Italy
Novartis Investigative Site
Meldola, FC, Italy
Novartis Investigative Site
Monza, MB, Italy
Novartis Investigative Site
Milan, MI, Italy
Novartis Investigative Site
Milan, MI, Italy
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.